🔬🕊️ Les Goldman’s Quiet Architecture: The Life and Work Behind $NWBO #DCVax
🌱 Part I. Foundations of a Builder
Good evening. Tonight we look back on the life of a man who did not seek the headlines, but who shaped the institutions behind them. Leslie J. Goldman was born in Chicago on April 22, 1945. His years would stretch from the end of the Second World War into the twenty-first century’s battle with cancer, a span of history where the survival of institutions was often as fragile as the survival of the people they served.
Goldman came of age at the University of Michigan. He graduated with a Bachelor of Arts in 1967, as America convulsed with civil rights marches, student protests, and a war in Southeast Asia that divided the country. Three years later, he earned his law degree from Michigan Law. He chose a road less traveled: public service, rather than private gain.
He became Special Counsel to Senator Adlai Stevenson III of Illinois. From 1970 to 1977, he sat in the engine room of democracy. Inflation surged. Oil shocks rattled the nation. Nuclear energy was both a promise and a fear. Goldman helped draft legislation that touched technology, trade, and environmental protection. These bills were not glamorous. They were the invisible girders of the economy. Here, Goldman learned a truth that would guide him for life: institutions survive only when their scaffolding is sound.
In 1977, the nation took a bold step. It created the Department of Energy, uniting nuclear power, oil, renewables, and conservation policy for the first time. Goldman was appointed Deputy General Counsel for International Affairs. It was no ceremonial title. He became one of the men tasked with giving the new agency its legal bones. He negotiated nuclear cooperation agreements, aligned U.S. policy with the Nuclear Non-Proliferation Treaty, and worked on oil import frameworks at a time when America feared shortages and inflation. The Department of Energy needed law and diplomacy. Goldman gave it both. He showed, early, a gift for helping fragile institutions stand.
But his career was not confined to energy. In 1978, Goldman moved into another arena under siege: the Public Broadcasting Service. PBS was still in its infancy. Each year Congress debated whether to fund it. Critics accused it of bias. Supporters called it a public good. Goldman became Vice President and General Counsel, a post he held for more than two decades. His work was mostly unseen, but its impact was in every living room. He defended PBS’s nonprofit charter. He built compliance systems that satisfied auditors and critics alike. He negotiated program rights that allowed Sesame Street to teach children their letters, NOVA to explain the stars, and Frontline to investigate corruption.
The 1980s brought the culture wars to PBS. Budgets were threatened. Some in Washington wanted public television dismantled. Goldman held the line. Year after year, his arguments helped preserve funding. His contracts ensured programs could continue. By the 1990s, PBS had become a trusted voice in American life. Goldman’s contribution was never on camera, but it was decisive. He had once again taken a fragile institution and given it the strength to endure.
After two decades defending public broadcasting, Goldman entered the private sector. He became a senior partner at Skadden, Arps, Slate, Meagher & Flom, one of the most powerful law firms in the world. His specialty was project finance and international transactions. These were the years of globalization, when billions of dollars flowed into infrastructure projects across continents. Goldman worked on power plants in Asia, pipelines in Latin America, and telecommunication networks in emerging markets.
His lesson to younger attorneys was simple. Contracts are only as strong as the environments in which they live. A financing agreement in Brazil or Indonesia could not be judged by its text alone. It had to survive currency devaluations, regime changes, and political unrest. Goldman’s deals were known for their durability. Projects structured under his guidance withstood volatility. He was again performing the same role he had played at DOE and PBS: he was not the public face, but the quiet architect of survival.
By the early 2000s, Goldman had achieved what most lawyers only dream of. He had shaped legislation in Washington, preserved public broadcasting, and structured global transactions. He could have stepped back. Instead, he chose a frontier more fragile than any he had faced before. He joined a small company called Northwest Biotherapeutics. Its mission was bold: to turn a patient’s own dendritic cells into a vaccine against cancer.
At the time, this was closer to science fiction than science fact. Few believed it could be done. Many companies had tried and failed. Trials collapsed for lack of money. Regulators were skeptical. Investors were wary. Goldman saw what others did not. He saw an institution in its most fragile state. And he did what he had always done. He stepped in to build its scaffolding.
This was not the secure ground of PBS or the halls of Skadden. It was the riskiest terrain of all: a small biotech fighting for survival, trying to deliver hope to patients with glioblastoma, one of the deadliest cancers known. Goldman was no scientist. He did not run trials or publish papers. But he understood that science cannot reach patients unless someone defends the institution carrying it. At Northwest Biotherapeutics, he would take on that fight.
💰 Part II. Holding the Line on Finances
When Les Goldman joined Northwest Biotherapeutics, he found a company with promise in its science but almost no margin for error in its finances. The challenge was stark. The Phase III trial in glioblastoma was already underway, involving more than three hundred patients across nearly a hundred hospitals. Each biopsy, each MRI, each dose of chemotherapy combined with DCVax had to be paid for. The company did not have the resources to guarantee completion.
Wall Street had little patience for a small firm pursuing a novel idea. Investors saw only risk. Yet Goldman understood that without financing, there would be no trial, and without a trial, there would be no evidence. And so he did what he had always done: he found ways to extend time.
By 2016, the company hit a breaking point. Under Nasdaq rules, Northwest could not issue more than twenty percent of its outstanding shares without shareholder approval if the stock was trading below book value. Northwest had already exceeded that threshold. Without fresh capital, the trial would collapse.
Goldman and the board made a decision that shocked many: they voluntarily withdrew from Nasdaq. Prestige was sacrificed. But survival was preserved. On the over-the-counter market, the company could raise the funds it needed without restriction. Critics called it defeat. Goldman knew it was life support. Without it, there would have been nothing left to criticize.
What followed were years of difficult financings. Convertible notes. Bridge loans. Standby equity facilities. None of them glamorous, all of them necessary. Goldman orchestrated each with one principle in mind: buy more time.
A standby equity facility with Yorkville Advisors gave the company the right, but not the obligation, to sell stock in tranches as needed, up to fifty million dollars. To some investors, it seemed like surrender — endless dilution. But Goldman understood it as endurance. Rather than risk a massive offering that would devastate the share price, the company could draw down gradually. Each tranche stretched the runway a little further. Each infusion allowed the trial to continue another season.
Shareholders complained. Yet the trial continued. And in the world of oncology, continuing is everything. For the patients enrolled, each month meant that data was being collected, immune responses recorded, lives measured in numbers that regulators would one day evaluate. For Goldman, it was not a choice between perfect and flawed. It was a choice between survival and collapse.
Financing was not the only battle. Every small company must defend itself in filings with regulators and investors. In those years, skepticism was high. Could an autologous cell therapy ever scale? Could a trial using external controls be taken seriously? Could a company so small ever reach the finish line?
Goldman became the shield. He oversaw disclosures with precision. Quarterly reports, press releases, clinical updates — all were written with his eye for credibility. He knew that exaggeration would invite dismissal. Careful understatement, on the other hand, could withstand scrutiny. In each filing he favored sober truth over hopeful spin.
Behind the scenes, he coordinated legal strategies to keep the trial compliant with regulators in both the United States and Europe. The Food and Drug Administration required documentation that the trial’s methodology was rigorous. The Medicines and Healthcare products Regulatory Agency in the United Kingdom was preparing its own frameworks for advanced therapies. Goldman ensured that the company’s submissions met each evolving standard.
Every dollar raised, every filing defended, had one purpose: buy time for the science. Dendritic cells are the generals of the immune system, directing T cells to recognize and attack tumors. DCVax-L, Northwest’s lead candidate, was designed to harness that power in glioblastoma, a disease where few treatments had ever shown success.
Goldman understood that the trial itself was the company’s greatest asset. If it reached the end and showed survival benefit, everything else would follow. If it failed, nothing else mattered. His financing maneuvers, his defensive legal strategies, his sober filings — all were scaffolding to protect that fragile effort.
By the late 2010s, Northwest had become a company many dismissed as too small, too slow, too beaten down by dilution. But Goldman knew differently. It was still alive. The trial was still running. Data was still being collected. And as long as that was true, hope remained.
🏛️ Part III. Building Regulatory Credibility
Survival alone was not enough. To matter, Northwest’s science had to earn credibility in the eyes of regulators. The Phase III trial in glioblastoma was unconventional. Instead of randomizing patients to a placebo arm, the company used externally controlled cohorts from leading institutions. For traditionalists, this design was heresy. But for patients, it was humane. Goldman knew that unless regulators could be persuaded, the trial’s results would never count.
He oversaw every disclosure with this in mind. Each quarterly filing, each clinical update, was written not for the impatient trader but for the regulator who might one day judge whether the data could be trusted. His discipline gave the company credibility.
In the United States, the Food and Drug Administration required that the company justify its use of external controls. In the United Kingdom, regulators were preparing a new pathway for advanced therapies known as Statutory Instrument 87. Under SI 87, therapies like DCVax could be reviewed adaptively, with flexibility for unusual trial designs. Goldman anticipated this. He ensured Northwest’s documentation was meticulous, its ethics defensible, its science explained in sober language. In doing so, he placed the company on rails toward a future many believed was closed.
But regulators demand more than numbers. They want to see that a therapy can be made reliably, consistently, and at scale. Personalized therapies are often criticized as unscalable. Goldman understood that manufacturing was not a footnote — it was a pillar. Without it, no trial result would ever become a product.
The answer was Sawston. In partnership with Advent BioServices, Northwest built an eighty-eight-thousand–square-foot facility in the English countryside. It housed cleanrooms for cell preparation, cryogenic storage for millions of vials, and production systems designed for reproducibility. The task was enormous. Years of construction. Thousands of pages of filings. Endless inspections. Goldman’s hand was evident at every stage.
In March 2023, Advent received a full commercial manufacturing license from the UK’s MHRA. It was one of the first such licenses for autologous cancer vaccines in the country. It authorized not just clinical supply but global export. Behind that achievement lay more than 1,600 documents and inspections. And on those documents, one often found Goldman’s name. He had ensured accuracy, compliance, and credibility. The fragile had been placed inside a fortress.
Then, in November 2022, came the moment of proof. After more than a decade of patient enrollment, monitoring, and analysis, the results of the Phase III glioblastoma trial were published in JAMA Oncology. For a small company like Northwest, this was as momentous as planting a flag on the moon.
The findings were extraordinary. For newly diagnosed patients, the five-year survival rate nearly doubled. For recurrent disease, where prognosis is often measured in months, a subset of patients lived years longer. Toxicity was minimal. Grade four or five side effects — the deadly ones — were almost nonexistent.
The design had been controversial. Critics doubted regulators would ever accept external controls. But publication in JAMA proved otherwise. Seventy co-authors from leading hospitals lent their names. The peer-review process validated the methodology. What once seemed impossible was now undeniable.
For families, it meant hope. For oncology, it meant that dendritic cell vaccines had crossed from theory into practice. And for Goldman, it was vindication. Without his financings, the trial would have ended. Without his filings, regulators would have dismissed the results. Without his discipline, the company would have collapsed. Instead, the data was published, the science validated, the hope extended.
⚙️ Part IV. Scaling the Science with Flaskworks
Even with promising data and a licensed factory, one challenge remained: scale. Critics argued that personalized immunotherapies could never be produced quickly or cheaply enough to matter. Goldman understood that the science needed not just proof, but practicality.
In 2020, Northwest acquired Flaskworks, a small company born out of Harvard’s Wyss Institute. Flaskworks had developed Eden, a closed-system bioreactor that could automate the manufacturing of dendritic cell vaccines. In place of sprawling cleanrooms and armies of technicians, Eden could prepare multiple patient batches at once, in smaller, less costly facilities.
This was not just an operational improvement. It was a survival breakthrough. Automation promised reproducibility, cost reductions, and the kind of scalability regulators and payors demanded. Goldman guided the acquisition, ensuring the contracts, rights, and disclosures were airtight. Once again, he did what he always did: he built scaffolding strong enough to hold the weight of fragile science.
But ownership matters as much as production. In biotechnology, intellectual property is the moat that protects innovation. Goldman recognized that if Northwest was to endure, it needed to secure the frontier of dendritic cell science.
Through Roswell Park Comprehensive Cancer Center, Northwest licensed next-generation technologies developed by Dr. Pawel Kalinski and colleagues. These included maturation protocols that supercharged dendritic cells with cytokines like IL-1Ăź, TNF, and interferon gamma, producing cells better able to prime T-cells. They also included regimens to reprogram the tumor microenvironment, dismantling the suppressive barriers cancers erect.
These technologies made dendritic cell vaccines more potent and durable. By securing exclusive rights, Northwest did more than protect a trial. It claimed a franchise. Goldman’s background at Skadden gave him the experience to structure these agreements so they were defensible and lasting. He was not just protecting today’s therapy. He was building tomorrow’s arsenal.
Even as Goldman strengthened the company’s foundations in science, manufacturing, and law, another threat emerged — this one from the marketplace itself. Northwest’s stock became a target of relentless short selling. Supporters alleged that market makers were engaging in spoofing: placing vast numbers of fake sell orders to push the price down, only to cancel them moments later.
On May 10, 2022, the company presented its long-awaited Phase III results. It should have been a triumph. Instead, the share price collapsed by more than eighty percent in a single day, falling from just over two dollars to thirty-six cents. Over $1.6 billion in value evaporated.
Most small biotechs would have accepted defeat. Goldman chose to fight. In December 2022, Northwest filed suit against seven of the most powerful firms in finance, including Citadel Securities and Virtu Americas. The complaint alleged a multi-year campaign that forced the company to issue nearly fifty million shares at artificially depressed prices.
For a small biotech to challenge Wall Street titans was almost unheard of. Yet Goldman saw it as the same fight he had waged all his life: defending the fragile against forces that could destroy it. In March 2025, a federal judge allowed the core allegations to proceed. It was not yet victory, but it was survival. The case moved forward. And with it, the principle that patients’ hope should not be trampled by manipulation.
🕯️ Part V. Passing at the Threshold
On August 16, 2025, Northwest Biotherapeutics announced that Les Goldman had passed away after a stroke. The timing was heavy with meaning. Sawston was licensed. The Marketing Authorisation Application was under active review. The JAMA Oncology publication had given DCVax global credibility. For the first time, the company stood on the threshold of possible approval.
Goldman did not live to see what came next. But his work was already plain. Without his financings, the trial would have failed. Without his filings, regulators would have dismissed the data. Without his defense, the markets would have crushed the company. With him, the fragile had endured.
The company’s public statement expressed appreciation for his years of service to shareholders and patients. The words were brief. For those who understood the journey, they carried the weight of history. Goldman had been the quiet architect who kept the mission alive when collapse seemed inevitable. His passing was not just the loss of an executive. It was the loss of the man who had held the scaffolding in place long enough for the science to stand.
🌍 Part VI. A Pattern Across a Life
When we look back across his career, a thread is visible, stitched through decades. At the Department of Energy, he gave a fledgling agency its legal shape. At PBS, he defended public broadcasting until it grew strong. At Skadden, he built global projects that endured through political and economic storms. And at Northwest Biotherapeutics, he preserved a fragile company carrying a fragile therapy until it had the chance to prove itself.
The arenas were different. The role was the same. He was the architect of survival. He was the defender of the fragile.
🧬 Part VII. His Contribution to Mankind
What, then, was his contribution to mankind? It was not in the lab bench experiments or the clinical procedures. It was in endurance itself.
Because of Goldman, Northwest survived. And because Northwest survived, patients with glioblastoma now live longer. Families have been given more time. Parents have seen more of their children. Children have kept their parents longer.
His contribution was measured not in profits or headlines, but in time. Time for a company to continue. Time for a therapy to prove itself. And most profoundly, time for patients to live. In the human calculus, there is no higher gift.
🕊️ Part VIII. Epilogue
Les Goldman never sought fame. He worked in the background, not the spotlight. Yet history depends on such figures. Institutions collapse without their architects. Science falters without its defenders.
Northwest Biotherapeutics would not stand where it does today without him. That is not speculation. It is fact. Remove his financings, and the trial would have ended. Remove his filings, and regulators would have dismissed the data. Remove his defense, and the markets would have crushed the company. With him, it endured.
And his pattern did not begin at Northwest. At the Department of Energy, he gave an agency international credibility. At PBS, he defended a broadcaster that taught children to read and brought science into American homes. At Skadden, he built global projects that withstood economic storms. At Northwest, he carried those same instincts into the most human of missions: the fight against cancer. The thread is clear. Wherever fragility threatened collapse, Goldman built the scaffolding that let others succeed.
His legacy is not etched in headlines, but in lives. It rests in the quiet architecture of survival. It will endure as long as patients live longer because he gave their therapy the chance to reach them.
Rest in peace, Les Goldman. Your life’s work endures.
Market Data 
Markets 
